Moberg Pharma AB (publ)

OM:MOB Stock Report

Market Cap: SEK 493.5m

Moberg Pharma Future Growth

Future criteria checks 5/6

Moberg Pharma is forecast to grow earnings and revenue by 93.6% and 59% per annum respectively while EPS is expected to grow by 93.1% per annum.

Key information

93.6%

Earnings growth rate

93.09%

EPS growth rate

Pharmaceuticals earnings growth35.3%
Revenue growth rate59.0%
Future return on equityn/a
Analyst coverage

Low

Last updated19 Feb 2026

Recent future growth updates

Recent updates

We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn

Nov 07
We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn

Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being

May 16
Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being
User avatar

Norway Expansion And EU Approvals Will Strengthen Future Position

Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.

Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth

Feb 12
Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Nov 16
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Jan 17
Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

Dec 03
Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

Earnings and Revenue Growth Forecasts

OM:MOB - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20289536N/AN/A1
12/31/2027569N/A171
12/31/202623-22N/A-201
12/31/202514-27-61-17N/A
9/30/202512-258-71-16N/A
6/30/202512-255-80-14N/A
3/31/202513-251-92-21N/A
12/31/202410-255-90-16N/A
9/30/20249-18-115-27N/A
6/30/20245-23-134-33N/A
3/31/20241-23-139-31N/A
12/31/2023N/A-21-157-33N/A
9/30/2023N/A-18-134-29N/A
6/30/20230-16-105-21N/A
3/31/20230-16-96-16N/A
12/31/20220-16-85-17N/A
9/30/20220-17-75-14N/A
6/30/2022N/A-16-70-12N/A
3/31/2022N/A-16-56-7N/A
12/31/2021N/A-16-47-15N/A
9/30/2021348-44-9N/A
6/30/2021347-46-12N/A
3/31/2021345-58-16N/A
12/31/2020347-52-10N/A
6/30/20205020-474N/A
6/30/201931-8N/A-76N/A
3/31/201945531N/A88N/A
12/31/20185-28N/A74N/A
9/30/20183419N/A87N/A
6/30/201834019N/A109N/A
3/31/20183346N/A68N/A
12/31/201743911N/A54N/A
9/30/2017438-1N/A30N/A
6/30/20174340N/A-44N/A
3/31/201736935N/A-17N/A
12/31/201633433N/A-18N/A
9/30/201629936N/A-21N/A
6/30/201626132N/A12N/A
3/31/20162829N/A32N/A
12/31/201528626N/A31N/A
9/30/201527625N/A34N/A
6/30/201526020N/A30N/A
3/31/201522619N/A14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).

Earnings vs Market: MOB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MOB is expected to become profitable in the next 3 years.

Revenue vs Market: MOB's revenue (59% per year) is forecast to grow faster than the Swedish market (1% per year).

High Growth Revenue: MOB's revenue (59% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MOB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/19 04:28
End of Day Share Price 2026/03/19 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moberg Pharma AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bjorn RydellABG Sundal Collier Sponsored
Klas PykNordea Markets
Mats HyttingeRedeye